Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

A Phase I, Double-blind, Randomised, Single Centre, Parallel Group, Single-dose, Dose-escalation, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of DNDI-0690 After Oral Dosing in Healthy Subjects

This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose. This is the first time the test medicine DNDI-0690 will be administered to humans.

Study Overview

• Status: Completed
• Conditions: Visceral Leishmaniasis; Cutaneous Leishmaniases
• Intervention / Treatment: Drug: DNDI-0690; Drug: Placebo of DNDI-0690

Detailed Description

DNDI-0690 is intended to be used as oral treatment for Visceral Leishmaniasis with potential for the cutaneous form of the disease, Cutaneous Leishmaniasis. The present protocol describes the first-in-human (FIH) study with DNDI-0690.

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Nottingham, United Kingdom
    • Quotient Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 56 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy males (Cohorts 1 to 7) or healthy WONCBP (Cohort 8)
• 18 to 55 years (Cohorts 1 to 7) or 18 to 60 years (Cohort 8)of age at the time of signing informed consent
• Body mass index (BMI) of 18.0 to 30.1 kg/m2 as measured at screening
• General good physical health determined by medical and surgical history, physical examination, 12-lead ECG, vital signs and clinical laboratory tests
• Normal blood pressure: Systolic blood pressure between ≥90 and ≤140 mmHg, Diastolic blood pressure ≤90 mmHg, measured after 10 min rest in supine position at screening, admission and pre-dose
• A resting Heart Rate (HR) between ≥40 and ≤90 bpm measured after 10 min rest in supine position at screening, admission and pre-dose
• ECG recording without clinically significant abnormality, including QTcF measure of ≤450 msec (male) or ≤470 msec (female) at screening, admission and pre-dose
• Having had no febrile seizures or infectious illness for at least 7 days prior to administration of the Investigational Medicinal Product (IMP)
• Must be willing and able to communicate and participate in the whole study
• Must provide written informed consent
• Must agree to adhere to the contraception requirements and life-style restrictions defined in the protocol

Exclusion Criteria:

• Subjects who have received any IMP in a clinical research study within the 3 months or 90 days prior to Day 1
• Subjects who are study site employees, or immediate family members of a study site or sponsor employee
• Subjects who have previously been enrolled in this study and/or have received DNDI-0690 previously
• History of any drug or alcohol abuse in the past 2 years
• Demonstrating excess in caffeine/xanthine consumption (more than 6 cups of coffee or equivalent a day)
• Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type). As confirmed by a positive alcohol breath test at screening or admission
• Current smokers and those who have smoked within the last 12 months. As confirmed by a breath carbon monoxide reading of greater than 10 ppm at screening or admission
• Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
• Females of childbearing potential including those who are pregnant or lactating (all female subjects must have a negative serum pregnancy test at screening and admission). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, bilateral tubal ligation, bilateral tubal occlusion and bilateral oophorectomy) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle stimulating hormone [FSH] concentration ≥40 IU/L)
• Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
• Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis (especially aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), creatinine, and blood urea nitrogen (BUN)) as judged by the investigator (laboratory parameters are listed in Appendix 1). Subjects with Gilbert's syndrome are allowed
• Confirmed positive drugs of abuse test result
• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
• Evidence of renal impairment at screening or admission, as indicated by an estimated creatinine clearance (CLcr) of <80 mL/min using the Cockcroft-Gault equation
• History of clinically significant cardiovascular, renal, hepatic, neurological (especially seizures), immunological, psychiatric, myopathies, bleeding tendency, respiratory and particularly gastrointestinal (GI) disease, especially peptic ulceration and chronic gastritis, GI bleeding, ulcerative colitis, Crohn's Disease or Irritable Bowel Syndrome, as judged by the investigator
• History of additional risk factors for Torsades des Pointe (eg heart failure, hypokalaemia, family history of long QT syndrome)
• Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency
• Any relevant GI complaints within 7 days of dosing
• Subjects with a history of cholecystectomy or gall stones (Cohort 7 only)
• Serious adverse reaction or clinically relevant hypersensitivity to any drug or the formulation excipients (Hypromellose [HPMC], sodium lauryl sulphate [SLS], sucrose, croscarmellose sodium and magnesium stearate)
• Presence or history of clinically significant allergy requiring treatment (including asthma, urticaria, clinically significant allergic rash or other severe allergic diathesis), as judged by the investigator. Hay fever is allowed unless it is active
• Donation or loss of greater than 500 mL of blood within the previous 3 months or more than 100 mL within 30 days before signing Informed Consent Form (ICF) to this trial
• Subjects who are taking, or have taken, any prescribed or over-the-counter drug (including anti-acid drugs) or vitamins/herbal remedies (eg St. John's Wort and others which are known to interfere with the Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) metabolic pathways) or HRT in the 21 days before IMP administration. Administration of up to 4 g of paracetamol per day within 7 days of IMP administration is allowed
• Surgery within 12 weeks prior to screening, with the exception of appendectomy
• Any surgery (eg gastric bypass) or medical condition that may affect absorption of orally administered drugs
• Failure to satisfy the investigator of fitness to participate for any other reason

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

11

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Active DNDI-0690 male 10mg fasting; Single dose 10mg male fasting	Drug: DNDI-0690; capsules of 10, 100 and 200 mg
Placebo Comparator: Placebo male fasting; Single dose placebo male fasting	Drug: Placebo of DNDI-0690; capsules of matching placebo
Experimental: Active DNDI-0690 male 30mg fasting; Single dose 30mg male fasting	Drug: DNDI-0690; capsules of 10, 100 and 200 mg
Experimental: Active DNDI-0690 male 150mg fasting; Single dose 150mg male fasting	Drug: DNDI-0690; capsules of 10, 100 and 200 mg
Experimental: Active DNDI-0690 male 400mg fasting; Single dose 400mg male fasting	Drug: DNDI-0690; capsules of 10, 100 and 200 mg
Experimental: Active DNDI-0690 male 1200mg fasting; Single dose 1200mg male fasting	Drug: DNDI-0690; capsules of 10, 100 and 200 mg
Experimental: Active DNDI-0690 male 3600mg fasting; Single dose 3600mg male fasting	Drug: DNDI-0690; capsules of 10, 100 and 200 mg
Placebo Comparator: Placebo male fed	Drug: Placebo of DNDI-0690; capsules of matching placebo
Experimental: Active DNDI-0690 400mg male fed; Single dose 400mg male fed	Drug: DNDI-0690; capsules of 10, 100 and 200 mg
Placebo Comparator: Placebo female fasting	Drug: Placebo of DNDI-0690; capsules of matching placebo
Experimental: Active DNDI-0690 1200mg female fasting; Single dose 1200mg female fasting	Drug: DNDI-0690; capsules of 10, 100 and 200 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability of DNDI-0690 by Assessing the Occurrence of Treatment-emergent adverse events (TEAEs)	number of subjects experiencing TEAEs classified by MedDRA (Medical Dictionary for Regulatory Activities) System Organ Class and Preferred Terms	from baseline up to 7-10 days post-dose
Safety and Tolerability of DNDI-0690 by Assessing the Changes in 12-lead electrocardiogram (ECG) parameters	corrected QT interval by Frideriecia's formula (QTcF) (msec)	from baseline up to 7-10 days post-dose
Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to liver function	aspartate aminotransferase (AST)	from baseline up 7-10 days post-dose
Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to liver function	alanine aminotransferase (ALT)	from baseline up 7-10 days post-dose
Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to renal function	creatinine (mg/dL)	from baseline up 7-10 days post-dose
Safety and Tolerability of DNDI-0690 by Assessing the Changes of Safety laboratory parameters related to renal function	creatinine clearance (CLcr)	from baseline up 7-10 days post-dose
Safety and Tolerability of DNDI-0690 by Assessing the Changes of Troponin I as a cardiac safety marker	Troponin I	4h, 9h, 24h and 48h post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity (AUC0-inf)	To assess plasma pharmacokinetic parameters	pre-dose up to 72 hours post-dose
Observed Maximum Concentration (Cmax)	To assess plasma pharmacokinetic parameters	pre-dose up to 72 hours post-dose
Time to Maximum Observed Plasma Concentration (Tmax)	To assess plasma pharmacokinetic parameters	pre-dose up to 72 hours post-dose
Apparent elimination half-life (T1/2)	To assess plasma pharmacokinetic parameters	pre-dose up to 72 hours post-dose

Collaborators and Investigators

• Sponsor: Drugs for Neglected Diseases
• Collaborators: Wellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable Elimination of Leishmaniasis
• Investigators: Principal Investigator: Sharan Sidhu, MD, Quotient Sciences

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2019
• Primary Completion (Actual): December 6, 2019
• Study Completion (Actual): July 2, 2020

Study Registration Dates

• First Submitted: April 9, 2019
• First Submitted That Met QC Criteria: April 25, 2019
• First Posted (Actual): April 26, 2019

Study Record Updates

• Last Update Posted (Actual): December 20, 2022
• Last Update Submitted That Met QC Criteria: December 16, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Keywords: healthy volunteer; single ascending dose; First-in-human
• Additional Relevant MeSH Terms: Skin Diseases; Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Skin Diseases, Parasitic; Skin Diseases, Infectious; Euglenozoa Infections; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral
• Other Study ID Numbers: DNDi-0690-01; 2018-002021-35 (EudraCT Number); QSC200932 (Other Identifier: Quotient Sciences)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: All IPD that underlie results in the publication will be shared at the time of publication of study results.
• IPD Sharing Time Frame: at the time of publication of study results.
• IPD Sharing Access Criteria: not yet defined
• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No